Response from Harmon et al to Letter Regarding Article, "Sudden Cardiac Death in National Collegiate Athletic Association Athletes"
- PMID: 39283930
- PMCID: PMC11822563
- DOI: 10.1161/CIRCULATIONAHA.124.070246
Response from Harmon et al to Letter Regarding Article, "Sudden Cardiac Death in National Collegiate Athletic Association Athletes"
Conflict of interest statement
Dr Ackerman is a consultant for Abbott, Boston Scientific, Bristol Myers Squibb, Daiichi Sankyo, Invitae, Medtronic, Tenaya Therapeutics, Thryv Therapeutics, and UpToDate. Dr Ackerman and Mayo Clinic are involved in an equity/royalty relationship with AliveCor, Anumana, ARMGO Pharma, and Pfizer. None of these entities was involved in this study. Dr Baggish has received funding from the National Institute of Health/National Heart, Lung, and Blood Institute, the National Football Players Association, the American Heart Association, and the American Medical Society for Sports Medicine to study cardiovascular outcomes among elite athletes and receives compensation for his role as team cardiologist from the US Olympic Committee/US Olympic Training Centers, US Soccer, and US Rowing. Dr Drezner has received funding from the American Medical Society for Sports Medicine, the American Heart Association, and the National Center for Catastrophic Sports Injury Research. Dr Harmon has received funding from the American Medical Society for Sports Medicine, Football Research, Inc, the Pac- 12, and the American Heart Association.
Comment on
-
Letter by Maron et al Regarding Article, "Sudden Cardiac Death in National Collegiate Athletic Association Athletes".Circulation. 2024 Sep 17;150(12):e255-e256. doi: 10.1161/CIRCULATIONAHA.123.068415. Epub 2024 Sep 16. Circulation. 2024. PMID: 39283935 No abstract available.
References
-
- Petek BJ, Churchill TW, Moulson N, Kliethermes SA, Baggish AL, Drezner JA, Patel MR, Ackerman MJ, Kucera KL, Siebert DM, et al. Sudden cardiac death in National Collegiate Athletic Association Athletes: a 20-year study. Circulation. 2024;149:80–90. doi: 10.1161/CIRCULATIONAHA.123.065908 - DOI - PMC - PubMed
-
- Ackerman MJ, Zipes DP, Kovacs RJ, Maron BJ; American Heart Association Electrocardiography and Arrhythmias Committee of Council on Clinical Cardiology, Council on Cardiovascular Disease in Young, Council on Cardiovascular and Stroke Nursing, Council on Functional Genomics and Translational Biology, and American College of Cardiology. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 10: the cardiac channelopathies: a scientific statement from the American Heart Association and American College of Cardiology. Circulation. 2015;132:e326–e329. doi: 10.1161/CIR.0000000000000246 - DOI - PubMed
-
- Moulson N, Petek BJ, Ackerman MJ, Churchill TW, Day SM, Kim JH, Kliethermes SA, Lampert R, Levine BD, Martinez MW, et al. Rationale and design of the ORCCA (Outcomes Registry for Cardiac Conditions in Athletes) Study. J Am Heart Assoc. 2023;12:e029052. doi: 10.1161/JAHA.122.029052 - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources